Seminars in Oncology
Volume 33, Issue 2 , Pages 186-194 , April 2006

Risk Stratification in Chronic Lymphocytic Leukemia

References 

  1. Chiorazzi N , Rai KR , Ferrarini M . Chronic lymphocytic leukemia . N Engl J Med . 2005;352:804–815
  2. Rozman C , Montserrat E . Chronic lymphocytic leukemia . N Engl J Med . 1995;333:1052–1057
  3. Zwiebel JA , Cheson BD . Chronic lymphocytic leukemia (Staging and prognostic factors) . Semin Oncol . 1998;25:42–59
  4. Dighiero G , Maloum K , Desablens B , et al.  French Cooperative Group on Chronic Lymphocytic Leukemia   Chlorambucil in indolent chronic lymphocytic leukemia . N Engl J Med . 1998;338:1506–1514
  5. Krober A , Seiler T , Benner A , et al.   V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia . Blood . 2002;100:1410–1416
  6. Montserrat E , Sanchez-Bisono J , Vinolas N , et al.   Lymphocyte doubling time in chronic lymphocytic leukaemia (Analysis of its prognostic significance) . Br J Haematol . 1986;62:567–575
  7. Rozman C , Montserrat E , Rodriguez-Fernandez JM , et al.   Bone marrow histologic pattern-the best single prognostic parameter in chronic lymphocytic leukemia (A multivariate survival analysis of 329 cases) . Blood . 1984;64:642–648
  8. Di Giovanni S , Valentini G , Carducci P , et al.   Beta-2-microglobulin is a reliable tumor marker in chronic lymphocytic leukemia . Acta Haematol . 1989;81:181–185
  9. Hallek M , Langenmayer I , Nerl C , et al.   Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early, nonsmoldering chronic lymphocytic leukemia . Blood . 1999;93:1732–1737
  10. Crespo M , Bosch F , Villamor N , et al.   ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia . N Engl J Med . 2003;348:1764–1775
  11. Damle RN , Wasil T , Fais F , et al.   Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia . Blood . 1999;94:1840–1847
  12. Dewald GW , Brockman SR , Paternoster SF , et al.   Chromosome anomalies detected by interphase fluorescence in situ hybridization (correlation with significant biological features of B-cell chronic lymphocytic leukaemia) . Br J Haematol . 2003;121:287–295
  13. Dohner H , Stilgenbauer S , Benner A , et al.   Genomic aberrations and survival in chronic lymphocytic leukemia . N Engl J Med . 2000;343:1910–1916
  14. Hamblin TJ , Davis Z , Gardiner A , et al.   Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia . Blood . 1999;94:1848–1854
  15. Lin K , Sherrington PD , Dennis M , Matrai Z , et al.   Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia . Blood . 2002;100:1404–1409
  16. Orchard JA , Ibbotson RE , Davis Z , et al.   ZAP-70 expression and prognosis in chronic lymphocytic leukaemia . Lancet . 2004;363:105–111
  17. Oscier DG , Gardiner AC , Mould SJ , et al.   Multivariate analysis of prognostic factors in CLL (Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors) . Blood . 2002;100:1177–1184
  18. Rassenti LZ , Huynh L , Toy TL , et al.   ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia . N Engl J Med . 2004;351:893–901
  19. Vasconcelos Y , Davi F , Levy V , et al.   Binet’s staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia . J Clin Oncol . 2003;21:3928–3932
  20. Binet JL , Auquier A , Dighiero G , et al.   A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis . Cancer . 1981;48:198–206
  21. Rai KR , Sawitsky A , Cronkite EP , et al.   Clinical staging of chronic lymphocytic leukemia . Blood . 1975;6:219–234
  22. Gray JL , Jacobs A , Block M . Bone marrow and peripheral blood lymphocytosis in the prognosis of chronic lymphocytic leukemia . Cancer . 1974;33:1169–1178
  23. Han T , Barcos M , Emrich L , et al.   Bone marrow infiltration patterns and their prognostic significance in chronic lymphocytic leukemia (correlations with clinical, immunologic, phenotypic, and cytogenetic data) . J Clin Oncol . 1984;2:562–570
  24. Kallander CF , Simonsson B , Gronowitz JS , et al.   Serum deoxythymidine kinase correlates with peripheral lymphocyte thymidine uptake in chronic lymphocytic leukemia . Eur J Haematol . 1987;38:331–337
  25. Kallander CF , Simonsson B , Hagberg H , et al.   Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia . Cancer . 1984;54:2450–2455
  26. Knauf WU , Langenmayer I , Ehlers B , et al.   Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia . Leuk Lymphoma . 1997;27:523–532
  27. Keating MJ . Chronic lymphocytic leukemia in the next decade (Where do we go from here?) . Semin Hematol . 1998;35:27–33
  28. Keating MJ , O’Brien S , Albitar M , et al.   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4079–4088
  29. Tobin G , Thunberg U , Johnson A , et al.   Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia . Blood . 2002;99:2262–2264
  30. Tobin G , Thunberg U , Johnson A , et al.   Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s (Implicating recognition of a common antigen epitope) . Blood . 2003;101:4952–4957
  31. Tobin G , Thunberg U , Karlsson K , et al.   Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia . Blood . 2004;104:2879–2885
  32. Widhopf GF , Rassenti LZ , Toy TL , et al.   Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins . Blood . 2004;104:2499–2504
  33. Rosenwald A , Alizadeh AA , Widhopf G , et al.   Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia . J Exp Med . 2001;194:1639–1647
  34. Ghia P , Guida G , Stella S , et al.   The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression . Blood . 2003;101:1262–1269
  35. Hamblin TJ , Orchard JA , Ibbotson RE , et al.   CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease . Blood . 2002;99:1023–1029
  36. Krober A , Kienle D , Seiler T , et al.   CLL subgroups carrying genetic high-risk features such as 11q-, 17p-, or V3-21 usage show a high rate of discorant VH and ZAP-70 status . Ann Oncol . 2005;16(suppl 5):35a; (abst 42)
  37. Heintel D , Kienle D , Shehata M , et al.   High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia . Leukemia . 2005;19:1216–1223
  38. Oppezzo P , Vasconcelos Y , Settegrana C , et al.   The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia . Blood . 2005;106:650–657
  39. Klein U , Yuhai T , Stolovitzky GA , et al.   Gene expression profiling of B cell chronic lymphozytic leukemia reveals a homogenous phenotype related to memory B cells . J Exp Med . 2001;194:1625–1638
  40. Haslinger C , Schweifer N , Stilgenbauer S , et al.   Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status . J Clin Oncol . 2004;22:3937–3949
  41. Kienle DL , Korz C , Hosch B , et al.   Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes . J Clin Oncol . 2005;23:3780–3792
  42. Beitz LO , Fruman DA , Kurosaki T , et al.   SYK is upstream of phosphoinositide 3-kinase in B cell receptor signaling . J Biol Chem . 1999;274:32662–32666
  43. Stilgenbauer S , Kröber A , Winkler D , et al.   VH mutation status and genomic aberrations in the prospective CLL1 trial (Binet A) of the German CLL Study Group (GCLLSG) . Blood . 2002;100(suppl 1):168; (abstr 628)
  44. Bergmann M , Eichhorst B , Busch R , et al.   Elevated thymidine kinase and short lymphocyte doubling time in combination with unfavourable cytogenetics or unmutated IgVH status are strong predictors for high individual risk for rapid disease progression in patients with B-CLL in Binet A stage (An interim report from the CLL1 Protokoll of the German CLL Study Group (GCLLSG)) . Blood . 2003;102:665a; (abstr 2464)
  45. Eichhorst B , Busch R , Hopfinger G , et al.   Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with advanced chronic lymphocytic leukemia . Blood . 2006;107:885–891
  46. Krober A , Bloehdorn J , Hafner S , et al.   Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia . J Clin Oncol . 2006; Jan 27 [Epub ahead of print]
  47. Dohner H , Stilgenbauer S , James MR , et al.   11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis . Blood . 1997;9:2516–2522
  48. el Rouby S , Thomas A , Costin D , et al.   p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression . Blood . 1993;2:3452–3459
  49. Geisler CH , Philip P , Christensen BE , et al.   In B-cell chronic lymphocytic leukaemia chromosome 17 abnormalities and not trisomy 12 are the single most important cytogenetic abnormalities for the prognosis (A cytogenetic and immunophenotypic study of 480 unselected newly diagnosed patients) . Leuk Res . 1997;21:1011–1023
  50. Dohner H , Fischer K , Bentz M , et al.   p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias . Blood . 1995;85:1580–1589
  51. Stilgenbauer S , Dohner H . Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy . N Engl J Med . 2002;347:452–453
  52. Lozanski G , Heerema NA , Flinn IW , et al.   Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions . Blood . 2004;103:3278–3281
  53. Maloum K , Magnac C , Cazin B , et al.   Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. Predictive value of mutational IgVH gene status for incomplete response and relapse after oral fludarabine phosphate (fludara oral) and cyclophosphamide in previously untreated CLL patients . Blood . 2003;102:35a; (abstr 110)
  54. Milligan DW , Fernandes S , Dasgupta R , et al.   Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses . Blood . 2005;105:397–404
  55. Dreger P , Montserrat E . Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia . Leukemia . 2002;16:985–992
  56. Ritgen M , Lange A , Stilgenbauer S , et al.   Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia . Blood . 2003;101:2049–2053
  57. Dreger P , Stilgenbauer S , Benner A , et al.   The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia (A risk-matched analysis based on the VH gene mutational status) . Blood . 2004;103:2850–2858
  58. Ritgen M , Stilgenbauer S , von Neuhoff N , et al.   Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status (Implications of minimal residual disease measurement with quantitative PCR) . Blood . 2004;104:2600–2602

 Supported by Wilhelm Sander-Stiftung (2003.086.1, 2001.004.2), Deutsche Krebshilfe (106116, 70-3173-Tr 3 B4), Fresenius Stiftung (CLL4VH), Amgen, Roche, and Schering.

PII: S0093-7754(06)00026-1

doi: 10.1053/j.seminoncol.2006.01.017

Seminars in Oncology
Volume 33, Issue 2 , Pages 186-194 , April 2006

Article Tools

* Image Usage & Resolution